Neurological adverse events of immune checkpoint inhibitors: an update of clinical presentations, diagnosis, and management

A Farina, M Villagrán-García, J Honnorat - Revue Neurologique, 2023 - Elsevier
The use of immune checkpoint inhibitors (ICIs) has represented a major advance in cancer
treatment. By enhancing endogenous immune responses to destroy cancer cells, ICIs can …

[HTML][HTML] Plasma Exchange in Patients With Myositis due to Immune Checkpoint Inhibitor Therapy

N Katyal, TR Katsumoto… - Journal of Clinical …, 2023 - journals.lww.com
Immune checkpoint inhibitors used to treat malignancies may lead to various immune-
related adverse events (irAEs) including conditions such as myositis and myasthenia gravis …

[HTML][HTML] Raising awareness of immune-related side effects in oncological patients under palliative care: a report of two cases

A Strunk, YN Batzler, M Ziemer… - Annals of Palliative …, 2023 - apm.amegroups.org
Background: Immune checkpoint inhibitors (ICI) have emerged as a successful treatment
option for diverse cancer entities. However, ICI therapy can be associated with immune …

[PDF][PDF] Raising awareness of immune-related side effects in oncological patients under palliative care: two cases report

A Strunk, YN Batzler, M Ziemer… - Annals of Palliative …, 2023 - cdn.amegroups.cn
Background: Immune checkpoint inhibitors (ICI) have emerged as a successful treatment
option for diverse cancer entities. However, ICI therapy can be associated with immune …

Diagnostic et traitement des complications neurologiques des immunothérapies anticancéreuses

A Farina, B Joubert - Pratique Neurologique-FMC, 2023 - Elsevier
Résumé Les immunothérapies anticancéreuses sont des traitements de développement
récent qui stimulent l'immunité antitumorale des patients atteints de cancer, soit au moyen …

Full-course management of therapy based on immune checkpoint inhibitors for advanced non-small cell lung cancer.

G Yaping, W Jun - Chinese Journal of Cancer Biotherapy, 2023 - search.ebscohost.com
Immunotherapy based on immune checkpoint inhibitor (ICI) has become the main treatment
strategy for advanced non-small cell lung cancer (NSCLC). By releasing immune checkpoint …